Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (929) 929
Book Chapter (8) 8
Newsletter (8) 8
Magazine Article (3) 3
Newspaper Article (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (658) 658
humans (652) 652
life sciences & biomedicine (639) 639
fenofibrate (496) 496
male (460) 460
fenofibrate - therapeutic use (372) 372
female (369) 369
middle aged (327) 327
fenofibrate - adverse effects (320) 320
hypolipidemic agents - therapeutic use (278) 278
hypolipidemic agents - adverse effects (244) 244
biological and medical sciences (222) 222
medical sciences (217) 217
pharmacology & pharmacy (207) 207
aged (200) 200
adult (189) 189
fenofibrate - pharmacology (174) 174
animals (173) 173
drug therapy, combination (164) 164
fenofibrate - administration & dosage (156) 156
lipids (141) 141
risk factors (139) 139
cholesterol (129) 129
pharmacology. drug treatments (122) 122
diabetes (121) 121
hypolipidemic agents - administration & dosage (115) 115
dyslipidemias - drug therapy (114) 114
drug therapy (113) 113
triglycerides - blood (113) 113
treatment outcome (112) 112
cardiovascular system & cardiology (110) 110
hyperlipidemias - drug therapy (110) 110
hypolipidemic agents - pharmacology (107) 107
statins (101) 101
triglycerides (100) 100
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (93) 93
abridged index medicus (92) 92
cardiac & cardiovascular systems (92) 92
research (91) 91
endocrinology & metabolism (90) 90
fibric acids (88) 88
double-blind method (86) 86
cardiovascular disease (83) 83
type 2 diabetes (80) 80
general & internal medicine (74) 74
medicine, general & internal (72) 72
rats (72) 72
lipids - blood (70) 70
care and treatment (68) 68
cholesterol - blood (68) 68
cholesterol, hdl - blood (68) 68
fenofibrate - analogs & derivatives (68) 68
cholesterol, ldl - blood (67) 67
mice (66) 66
diabetes mellitus, type 2 - drug therapy (65) 65
dyslipidemia (65) 65
medicine & public health (65) 65
simvastatin (63) 63
cardiovascular diseases (61) 61
health aspects (61) 61
diabetes mellitus, type 2 - complications (60) 60
drug interactions (59) 59
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (57) 57
insulin resistance (55) 55
cardiovascular diseases - prevention & control (54) 54
cardiology (53) 53
general and cellular metabolism. vitamins (53) 53
hyperlipidemia (53) 53
analysis (51) 51
atherosclerosis (51) 51
dosage and administration (51) 51
ppar alpha - agonists (50) 50
biochemistry & molecular biology (49) 49
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (48) 48
internal medicine (48) 48
liver - drug effects (48) 48
anticholesteremic agents - therapeutic use (47) 47
fibrates (47) 47
medicine, research & experimental (47) 47
research & experimental medicine (47) 47
endocrinopathies (46) 46
cardiovascular (44) 44
ezetimibe (44) 44
hypercholesterolemia - drug therapy (44) 44
ppar alpha - metabolism (44) 44
metabolism (43) 43
hypertriglyceridemia - drug therapy (42) 42
medical research (42) 42
randomized controlled trials as topic (42) 42
rodents (42) 42
clinical trials (41) 41
fenofibrate - pharmacokinetics (41) 41
lipoproteins (41) 41
low density lipoproteins (41) 41
atorvastatin (40) 40
dyslipidemias - blood (40) 40
inflammation (40) 40
physiological aspects (40) 40
studies (40) 40
diabetes. impaired glucose tolerance (39) 39
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (879) 879
French (38) 38
Spanish (16) 16
Russian (7) 7
Chinese (6) 6
German (4) 4
Japanese (4) 4
Portuguese (4) 4
Italian (2) 2
Polish (2) 2
Czech (1) 1
Hungarian (1) 1
Persian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study
by Nicoletti, Paola and Aithal, Guruprasad P and Bjornsson, Einar S and Andrade, Raul J and Sawle, Ashley and Arrese, Marco and Barnhart, Huiman X and Bondon-Guitton, Emmanuelle and Hayashi, Paul H and Bessone, Fernando and Carvajal, Alfonso and Cascorbi, Ingolf and Cirulli, Elizabeth T and Chalasani, Naga and Conforti, Anita and Coulthard, Sally A and Daly, Mark J and Day, Christopher P and Dillon, John F and Fontana, Robert J and Grove, Jane I and Hallberg, Pär and Hernández, Nelia and Ibáñez, Luisa and Kullak-Ublick, Gerd A and Laitinen, Tarja and Larrey, Dominique and Lucena, M. Isabel and Maitland-van der Zee, Anke H and Martin, Jennifer H and Molokhia, Mariam and Pirmohamed, Munir and Powell, Elizabeth E and Qin, Shengying and Serrano, Jose and Stephens, Camilla and Stolz, Andrew and Wadelius, Mia and Watkins, Paul B and Floratos, Aris and Shen, Yufeng and Nelson, Matthew R and Urban, Thomas J and Daly, Ann K and International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium and Int Drug-Induced Liver Injury Cons and Drug-Induced Liver Injury Network and Int Serious Adverse Events Consort
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. 1078 - 1089
Gastroenterology and Hepatology | Side Effect | Medication | Liver Damage | Anti-Fungal Agent | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antifungal Agents - adverse effects | Naphthalenes - adverse effects | Humans | Middle Aged | Male | Sertraline - adverse effects | Fenofibrate - adverse effects | Chromosomes, Human, Pair 2 - genetics | Ticlopidine - adverse effects | Female | Odds Ratio | Chemical and Drug Induced Liver Injury - etiology | Platelet Aggregation Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Genes, MHC Class I - genetics | Chemical and Drug Induced Liver Injury - genetics | Terbinafine | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Alleles | HLA-A Antigens - genetics | Polymorphism, Single Nucleotide | Antidepressive Agents - adverse effects | Drugs | Medical research | Liver diseases | Liver | Genes | Genomics | Risk factors | Genetic polymorphisms | Analysis | Gastrointestinal diseases | Medicine, Experimental | Genetic research | Trade and professional associations | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology | side effect | medication | anti-fungal agent | liver damage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
by Ginsberg, Henry N and Elam, Marshall B and Lovato, Laura C and Crouse III, John R and Leiter, Lawrence A and Linz, Peter and Friedewald, William T and Buse, John B and Gerstein, Hertzel C and Probstfield, Jeffrey and Grimm, Richard H and Ismail-Beigi, Faramarz and Bigger, J. Thomas and Goff Jr, David C and Cushman, William C and Simons-Morton, Denise G and Byington, Robert P and The ACCORD Study Group and ACCORD Study Grp and ACCORD Study Group
The New England journal of medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 17, pp. 1563 - 1574
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simvastatin - therapeutic use | Myocardial Infarction - epidemiology | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Male | Fenofibrate - therapeutic use | Fenofibrate - adverse effects | Treatment Failure | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Drug Therapy, Combination | Hypolipidemic Agents - adverse effects | Stroke - prevention & control | Kaplan-Meier Estimate | Proportional Hazards Models | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sex Factors | Triglycerides - blood | Aged | Hypolipidemic Agents - therapeutic use | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Evaluation | Complications and side effects | Usage | Dosage and administration | Drug therapy, Combination | Drug therapy | Health aspects | Statins | Fibric acids | Cardiovascular disease | Lipids | Diabetes | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics
by Leonard, CE and Bilker, WB and Brensinger, CM and Han, X and Flory, JH and Flockhart, DA and Gagne, JJ and Cardillo, S and Hennessy, S
Clinical pharmacology and therapeutics, ISSN 0009-9236, 05/2016, Volume 99, Issue 5, pp. 538 - 547
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypoglycemia - epidemiology | Glipizide - administration & dosage | Humans | Middle Aged | Glipizide - adverse effects | Male | Fenofibrate - adverse effects | Incidence | Drug Interactions | Hypoglycemic Agents - administration & dosage | Female | Retrospective Studies | Sulfonylurea Compounds - administration & dosage | Glyburide - administration & dosage | Hypoglycemia - chemically induced | Glyburide - adverse effects | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Fenofibrate - administration & dosage | Sulfonylurea Compounds - adverse effects | Algorithms | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hypolipidemic Agents - administration & dosage | Aged | Hypoglycemic Agents - adverse effects | Cohort Studies | Care and treatment | Dosage and administration | Management | Hypoglycemia | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Risk factors | Public health | Index Medicus | Abridged Index Medicus | drug interactions | fibric acids | sulfonylurea compounds | hypoglycemia | cohort studies | hydroxymethylglutaryl-CoA reductase inhibitors | Medicaid | pharmacoepidemiology | propensity score
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST)
by Davidson, Michael H and Rosenson, Robert S and Maki, Kevin C and Nicholls, Stephen J and Ballantyne, Christie M and Mazzone, Theodore and Carlson, Dawn M and Williams, Laura A and Kelly, Maureen T and Camp, Heidi S and Lele, Aditya and Stolzenbach, James C
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 06/2014, Volume 34, Issue 6, pp. 1298 - 1306
hypertriglyceridemia | atorvastatin | carotid intima-media thickness | fenofibric acid | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Dyslipidemias - drug therapy | Double-Blind Method | Carotid Intima-Media Thickness | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Fenofibrate - analogs & derivatives | Male | Heptanoic Acids - adverse effects | Dyslipidemias - pathology | Fenofibrate - adverse effects | Atorvastatin Calcium | Dyslipidemias - blood | Fenofibrate - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text HMG-CoA Reductase Inhibitors and Myotoxicity
by Ucar M and Mjorndal T and Dahlqvist R
06/2000, Volume 22, Issue 6, 17
HMG CoA reductase inhibitors, adverse reactions | Lovastatin, adverse reactions | Pravastatin, adverse reactions | Arthralgia, drug-induced | Muscle pain, drug-induced | HMG CoA reductase inhibitors, drug interactions | HMG CoA reductase inhibitors, pharmacokinetics | Simvastatin, adverse reactions | Drug interactions | Cerivastatin, adverse reactions | Clofibrate, adverse reactions | Muscular disorders, drug-induced | Cholestyramine, adverse reactions | Colestipol, adverse reactions | Myositis, drug-induced | Fluvastatin, adverse reactions | Rhabdomyolysis, drug-induced | Nicotinic acid, adverse reactions | Fenofibrate, adverse reactions | Atorvastatin, adverse reactions | Bezafibrate, adverse reactions | Gemfibrozil, adverse reactions | Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Biological and medical sciences | Toxicity: nervous system and muscle | Medical sciences | Drug toxicity and drugs side effects treatment | Pharmacology. Drug treatments | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Risk Factors | Muscular Diseases - pathology | Muscular Diseases - chemically induced | Index Medicus
Book Review
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials
by Geng, Qiang and Ren, Jingyi and Chen, Hong and Lee, Chongyou and Liang, Wenqing
Current medical research and opinion, ISSN 0300-7995, 03/2013, Volume 29, Issue 3, pp. 181 - 188
Fenofibric acid | Statin | Adverse events | Meta-analysis | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Biological and medical sciences | Medical sciences | Drug toxicity and drugs side effects treatment | General and cellular metabolism. Vitamins | Pharmacology. Drug treatments | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypolipidemic Agents - adverse effects | Dyslipidemias - drug therapy | Kidney - drug effects | Creatine Kinase - blood | Lipoproteins, HDL - blood | Humans | Fenofibrate - administration & dosage | Fenofibrate - analogs & derivatives | Alanine Transaminase - blood | Fenofibrate - therapeutic use | Fenofibrate - adverse effects | Randomized Controlled Trials as Topic | Drug Therapy, Combination - adverse effects | Dyslipidemias - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Aspartate Aminotransferases - blood | Liver - drug effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lipids - blood | Hypolipidemic Agents - administration & dosage | Triglycerides - blood | Hypolipidemic Agents - therapeutic use | Lipoproteins, LDL - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
by Corpechot, Christophe and Chazouillères, Olivier and Rousseau, Alexandra and Le Gruyer, Antonia and Habersetzer, François and Mathurin, Philippe and Goria, Odile and Potier, Pascal and Minello, Anne and Silvain, Christine and Abergel, Armand and Debette-Gratien, Maryline and Larrey, Dominique and Roux, Olivier and Bronowicki, Jean-Pierre and Boursier, Jérôme and de Ledinghen, Victor and Heurgue-Berlot, Alexandra and Nguyen-Khac, Eric and Zoulim, Fabien and Ollivier-Hourmand, Isabelle and Zarski, Jean-Pierre and Nkontchou, Gisèle and Lemoinne, Sara and Humbert, Lydie and Rainteau, Dominique and Lefèvre, Guillaume and de Chaisemartin, Luc and Chollet-Martin, Sylvie and Gaouar, Farid and Admane, Farid-Hakeem and Simon, Tabassome and Poupon, Raoul
The New England journal of medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 23, pp. 2171 - 2181
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Bezafibrate - therapeutic use | Hypolipidemic Agents - adverse effects | Bile Acids and Salts - blood | Double-Blind Method | Humans | Middle Aged | Liver Cirrhosis, Biliary - drug therapy | Male | Bezafibrate - adverse effects | Cholangitis - drug therapy | Ursodeoxycholic Acid - therapeutic use | Cholangitis - etiology | Placebos - therapeutic use | Treatment Failure | Adult | Female | Hypolipidemic Agents - therapeutic use | Liver Cirrhosis, Biliary - complications | Usage | Care and treatment | Dosage and administration | Biliary cirrhosis | Research | Health aspects | Fibric acids | Antilipemic agents | Alkaline phosphatase | Laboratories | Liver | Gallbladder diseases | Biochemistry | Pruritus | Bilirubin | Phosphatase | Ursodeoxycholic acid | Hepatitis | Hepatology | Gastroenterology | Tumor necrosis factor-TNF | Creatinine | Hypertension | Liver diseases | Cholangitis | Fatigue | Myalgia | Patients | Cholesterol | Quality of life | Hospitals | Acids | Bezafibrate | Fibrosis | Prothrombin | Peroxisome proliferator-activated receptors | Bile | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Risk of adverse events with fibrates
by Alsheikh-Ali, Alawi A and Kuvin, Jeffrey T and Karas, Richard H
The American journal of cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 7, pp. 935 - 938
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Medical sciences | Hypolipidemic Agents - adverse effects | United States - epidemiology | Rhabdomyolysis - epidemiology | Humans | Hyperlipidemias - drug therapy | Middle Aged | Risk Factors | Male | Liver Diseases - epidemiology | Gemfibrozil - adverse effects | Fenofibrate - adverse effects | Treatment Failure | Rhabdomyolysis - chemically induced | Female | Aged | Chemical and Drug Induced Liver Injury | Complications and side effects | Gemfibrozil | Fibric acids | Cardiology | Drug therapy | Risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights